Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
InnoCan Pharma: Multi-Milliarden-Wert in diesem Pennystock?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
14 Leser
Artikel bewerten:
(0)

Clinical Trials Imaging Market by Modality (CT, MRI, PET, Ultrasound, Echocardiography, X-rays), End Users (Pharmaceutical Companies, CROs Medical device Manufacturers) & Products (Services, Software)

DUBLIN, Oct. 06 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/cw3dbz/clinical_trials) has announced the addition of the "Clinical Trials Imaging Market by Modality (CT, MRI, PET, Ultrasound, Echocardiography, X-rays), End User (Pharmaceutical Companies, CROs Medical device Manufacturers), Product (Services, software), and Region - Global Forecast to 2020" report to their offering.

The global clinical trials imaging market is expected to USD 981.53 Million by 2020 from USD 724.87 Million in 2015, at a CAGR of 6.25% between 2015 and 2020

The major drivers for the market include growth in pharmaceutical & biotechnology industries, increase in R&D funding and increasing number of CROs are driving the growth of the global clinical trials market. The emerging economies in developing countries and development of innovative new imaging modalities, contrast agents, molecular probes & radiopharmaceutical will provide opportunities and new trends for market growth.

The report provides a granular understanding of the clinical trials imaging market. This report segments the global clinical trials imaging market on the basis of products, modalities, end-users, and geographies. The product segments included in this report are services and software.

The modality segment includes CT, MRI, Ultrasound, PET, X-rays, ECHO and other modalities. The end-user segments included in this report are pharmaceutical companies, biotechnology companies, medical device companies/manufacturers, CROs & academic and government research institutes.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW). The report maps each test type and product segment in 11 geographic and regional segments.

The major players in this market include BioClinica, Inc. (U.S.), Biomedical Systems (U.S.), Cardiovascular Imaging Technologies (U.S.), ICON Public Limited Company (Ireland), Intrinsic Imaging, LLC (U.S.), IXICO, PLC (U.K.), PAREXEL International Corporation (U.S.), Radiant Sage, LLC (U.S.), VirtualScopic, Inc. (U.S.), and WorldCare Clinical, LLC (U.S.).

Key Topics Covered:

1 Introduction

2 Research Methodology



3 Executive Summary

4 Premium Insights

5 Market Overview

6 Clinical Trials Imaging Market, By Product

7 Clinical Trials Imaging Market, By Modality

8 Clinical Trials Imaging Market, By End User

9 Geographic Analysis

10 Competitive Landscape

11 Company Profiles

- Bioclinica, Inc.
- Biomedical Systems Corporation
- Cardiovascular Imaging Technologies, LLC
- Icon Public Limited Company
- Intrinsic Imaging LLC
- Ixico PLC
- Parexel International Corporation
- Radiant Sage LLC
- Virtualscopics, Inc.
- Worldcare Clinical, LLC

For more information visit http://www.researchandmarkets.com/research/cw3dbz/clinical_trials

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.